MX2022006525A - Activo de polipeptidos de lisina contra bacterias gram-negativas. - Google Patents

Activo de polipeptidos de lisina contra bacterias gram-negativas.

Info

Publication number
MX2022006525A
MX2022006525A MX2022006525A MX2022006525A MX2022006525A MX 2022006525 A MX2022006525 A MX 2022006525A MX 2022006525 A MX2022006525 A MX 2022006525A MX 2022006525 A MX2022006525 A MX 2022006525A MX 2022006525 A MX2022006525 A MX 2022006525A
Authority
MX
Mexico
Prior art keywords
negative bacteria
lysin polypeptides
active against
against gram
gram
Prior art date
Application number
MX2022006525A
Other languages
English (en)
Inventor
Raymond Schuch
Michael Wittekind
Simon Hoffenberg
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of MX2022006525A publication Critical patent/MX2022006525A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente descripción proporciona métodos y composiciones útiles para la mejora profiláctica y terapéutica y tratamiento de infecciones causadas por bacterias Gram-negativas, que incluyen Pseudomonas aeruginosa. La descripción proporciona además composiciones y métodos para incorporar y utilizar polipéptidos de lisina de la presente descripción para aumentar la eficacia de antibióticos generalmente adecuados para el tratamiento de la infección bacteriana Gramnegativa.
MX2022006525A 2015-09-17 2018-03-13 Activo de polipeptidos de lisina contra bacterias gram-negativas. MX2022006525A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220212P 2015-09-17 2015-09-17
US201562247619P 2015-10-28 2015-10-28

Publications (1)

Publication Number Publication Date
MX2022006525A true MX2022006525A (es) 2022-07-11

Family

ID=57121513

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018003101A MX2018003101A (es) 2015-09-17 2016-09-16 Activo de polipeptidos de lisina contra bacterias gram-negativas.
MX2018003100A MX2018003100A (es) 2015-09-17 2016-09-16 Uso de lisina para restaurar/aumentar la actividad antibacteriana en presencia de agente tensoactivo pulmonar de antibioticos inhibidos en el mismo.
MX2022006525A MX2022006525A (es) 2015-09-17 2018-03-13 Activo de polipeptidos de lisina contra bacterias gram-negativas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2018003101A MX2018003101A (es) 2015-09-17 2016-09-16 Activo de polipeptidos de lisina contra bacterias gram-negativas.
MX2018003100A MX2018003100A (es) 2015-09-17 2016-09-16 Uso de lisina para restaurar/aumentar la actividad antibacteriana en presencia de agente tensoactivo pulmonar de antibioticos inhibidos en el mismo.

Country Status (15)

Country Link
US (5) US11357833B2 (es)
EP (4) EP3349780B1 (es)
JP (3) JP7029805B2 (es)
KR (2) KR20180052754A (es)
CN (3) CN108135971A (es)
AU (3) AU2016324298B2 (es)
BR (2) BR112018005318A2 (es)
CA (2) CA2998507A1 (es)
ES (1) ES2934714T3 (es)
HK (1) HK1256628A1 (es)
IL (2) IL258123B (es)
MX (3) MX2018003101A (es)
RU (2) RU2728682C2 (es)
WO (2) WO2017049233A2 (es)
ZA (2) ZA201801316B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104780933B (zh) * 2012-05-09 2020-08-28 康特拉费克特公司 使用噬菌体溶素的生物膜预防、破坏和处理
BR112016030580B1 (pt) * 2014-06-26 2023-12-19 The Rockefeller University Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
AU2016324298B2 (en) 2015-09-17 2022-09-01 Contrafect Corporation Lysin polypeptides active against Gram-negative bacteria
CN111971058A (zh) * 2017-12-12 2020-11-20 康特拉费克特公司 对铜绿假单胞菌具有细菌活性的溶素及其衍生物的鉴定
WO2019126670A1 (en) 2017-12-22 2019-06-27 The Rockefeller University Recombinant pseudomonas aeruginosa lysins
US20190201344A1 (en) 2017-12-28 2019-07-04 Consegna Pharma Inc. Long acting opioid antagonists
US10988520B2 (en) 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
MX2020010071A (es) * 2018-03-29 2021-01-08 Contrafect Corp Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.
WO2019191633A2 (en) * 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3813796A4 (en) * 2018-05-23 2022-06-22 The Rockefeller University RECOMBINANT LYSINE
CN112867398A (zh) * 2018-06-22 2021-05-28 康特拉费克特公司 溶素及其衍生物使金黄色葡萄球菌和革兰氏阳性菌对抗生素重新敏感
CN110664881A (zh) * 2018-07-03 2020-01-10 上海海洋大学 抗水产致病性弗氏柠檬酸杆菌的药物及其制备方法
BR112020018787A2 (pt) * 2018-08-23 2021-03-09 Contrafect Corporation Constructos de polipeptídeo de lisina-peptídeo antimicrobiano (amp), lisinas, polinucleotídeos isolados que codificam os mesmos e usos dos mesmos
EP3873917A4 (en) * 2018-11-02 2022-08-17 The Rockefeller University COMPOSITIONS AND METHODS COMPRISING LYSOCINES AS BIOTECHNICAL ANTIMICROBIAL FOR USE IN TARGETING GRAM-NEGATIVE BACTERIA
CN114025782A (zh) * 2019-03-22 2022-02-08 康特拉费克特公司 治疗感染性心内膜炎的方法
AU2020256258A1 (en) * 2019-04-05 2021-11-04 Contrafect Corporation Lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosa, in the presence of human serum
WO2021011404A1 (en) * 2019-07-12 2021-01-21 Contrafect Corporation Therapeutic protein formulations comprising antibodies and uses thereof
CN110684760A (zh) * 2019-09-27 2020-01-14 吉林大学 一种杀灭葡萄球菌的基因工程裂解酶及制备方法和应用
MX2022011291A (es) 2020-03-11 2022-12-08 Telum Therapeutics S L Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas.
WO2021207679A1 (en) * 2020-04-10 2021-10-14 Liberty Biosecurity, Llc Polypeptide compositions and uses thereof
US20210324359A1 (en) * 2020-04-17 2021-10-21 Contrafect Corporation Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis
KR102228999B1 (ko) * 2020-08-27 2021-03-18 주식회사 라이센텍 폴리펩타이드 변이체 및 이를 포함하는 그람음성균에 대한 항생제
KR102224897B1 (ko) * 2020-05-22 2021-03-08 주식회사 라이센텍 신규한 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제
EP4074831A4 (en) * 2020-05-22 2023-08-09 Lysentech Co., Ltd. NEW POLYPEPTIDE, FUSION POLYPEPTIDE AND ANTIBIOTIC AGAINST GRAM-NEGATIVE BACTERIA INCLUDING THEM
KR102419028B1 (ko) * 2021-01-06 2022-07-08 주식회사 리신바이오 박테리오파지 유래 신규 재조합 엔도라이신 및 이의 용도
US11452757B2 (en) * 2021-02-25 2022-09-27 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2023018199A1 (ko) * 2021-08-09 2023-02-16 주식회사 레고켐바이오사이언스 신규 항생제 및 이의 용도
WO2023034646A2 (en) * 2021-09-03 2023-03-09 Aanika Biosciences, Inc. Lysecd7 variants and methods of using the same
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040131567A1 (en) 2002-07-08 2004-07-08 Wilkins Joe S. Antibacterial topical formulations
CN101094427B (zh) 2006-06-23 2010-05-12 华为技术有限公司 全网信令消息采集系统及方法
US8623811B2 (en) * 2007-07-26 2014-01-07 Revance Therapeutics, Inc. Antimicrobial peptide, compositions, and methods of use
MX360300B (es) 2009-06-26 2018-10-29 Katholieke Univ Leuven K U Leuven R&D Agentes antimicrobianos.
SG178440A1 (en) 2009-08-24 2012-04-27 Univ Leuven Kath New endolysin obpgplys
CN102021161A (zh) 2009-09-22 2011-04-20 昆山博青生物科技有限公司 一种制备肺炎链球菌噬菌体裂解酶的方法
CA2811472C (en) * 2010-09-17 2019-08-27 Tecnifar-Industria Tecnica Farmaceutica, S.A. Antibacterial phage, phage peptides and methods of use thereof
EP2468856A1 (en) 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
JP5187460B2 (ja) * 2011-02-22 2013-04-24 Ｄｉｃ株式会社 水性ウレタン樹脂組成物及びそれを用いて得られるフィルム及び光学フィルム
AU2012245357B2 (en) 2011-04-21 2017-06-08 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
US20140120074A1 (en) 2011-04-27 2014-05-01 Lysando Ag Antimicrobial agents
WO2013044055A2 (en) 2011-09-23 2013-03-28 Quantum Engineered Products, Inc. Low profile jack
BR112014027842A2 (pt) * 2012-05-09 2017-08-08 Contrafect Corp bacteriófago lisina e combinações de antibióticos contra bactérias gram-positivas
EP2679677A1 (en) 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US9139626B2 (en) 2012-09-13 2015-09-22 The Mitre Corporation Mitrecin A polypeptide with antimicrobial activity
EP2951548A2 (en) 2013-01-29 2015-12-09 Wideco Sweden AB System for monitoring pipeline leakage, pipeline element provided with the system, and method for mounting the monitoring system onto a pipeline
US10214564B2 (en) 2013-02-06 2019-02-26 Academia Sinica Antimicrobial peptides derived from hepatitis B virus core protein arginine-rich domain
WO2015070912A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
WO2015070911A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified kz144 endolysin sequence
AU2016324298B2 (en) * 2015-09-17 2022-09-01 Contrafect Corporation Lysin polypeptides active against Gram-negative bacteria

Also Published As

Publication number Publication date
RU2018107249A3 (es) 2020-01-10
EP4151228A2 (en) 2023-03-22
EP4151228A3 (en) 2023-06-14
CN108348574B (zh) 2022-11-01
US20190070269A1 (en) 2019-03-07
JP2022065075A (ja) 2022-04-26
BR112018005318A2 (pt) 2018-12-11
RU2724545C2 (ru) 2020-06-23
CN108135971A (zh) 2018-06-08
US20230050560A1 (en) 2023-02-16
IL258123A (en) 2018-05-31
EP3349780B1 (en) 2022-11-09
CN108348574A (zh) 2018-07-31
HK1256628A1 (zh) 2019-09-27
AU2022252850A1 (en) 2022-11-17
IL258122A (en) 2018-05-31
US11357833B2 (en) 2022-06-14
ZA201801315B (en) 2018-11-28
MX2018003100A (es) 2019-04-15
JP2018527378A (ja) 2018-09-20
US11413334B2 (en) 2022-08-16
CN116077630A (zh) 2023-05-09
RU2018107245A3 (es) 2019-10-18
US20200376096A1 (en) 2020-12-03
WO2017049233A3 (en) 2017-06-01
AU2016324298B2 (en) 2022-09-01
US20220362352A1 (en) 2022-11-17
JP7029805B2 (ja) 2022-03-04
KR20180052754A (ko) 2018-05-18
IL258122B (en) 2020-08-31
BR112018005316A2 (pt) 2018-12-11
WO2017049242A2 (en) 2017-03-23
MX2018003101A (es) 2018-12-17
RU2018107245A (ru) 2019-10-18
AU2016324298A1 (en) 2018-03-22
ES2934714T3 (es) 2023-02-24
US20190290672A1 (en) 2019-09-26
CA2998507A1 (en) 2017-03-23
AU2016324307B2 (en) 2021-10-21
RU2728682C2 (ru) 2020-07-31
US10744189B2 (en) 2020-08-18
CA2998484A1 (en) 2017-03-23
IL258123B (en) 2021-03-25
KR20180064417A (ko) 2018-06-14
EP3349780A2 (en) 2018-07-25
AU2016324307A1 (en) 2018-03-22
JP2018534247A (ja) 2018-11-22
WO2017049233A2 (en) 2017-03-23
WO2017049242A3 (en) 2017-06-01
ZA201801316B (en) 2018-11-28
RU2018107249A (ru) 2019-10-17
EP3349781A2 (en) 2018-07-25
EP4115897A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
MX2022006525A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
EP4282489A3 (en) Treatment of clostridium difficile infection
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
WO2016179440A3 (en) Antimicrobial therapy
MX2016015218A (es) Antibioticos macrociclicos de amplio espectro.
MX2019007613A (es) Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos.
WO2018208987A3 (en) Antibacterial compounds
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
WO2013122888A3 (en) Methods of treating bacterial infections
WO2015003816A3 (en) Cystobactamides
PH12019500360A1 (en) Antibiotic compounds
MX2020006191A (es) Bacteriocinas terapeuticas.
MX2021003084A (es) Compuestos antibacterianos.
MX2018006190A (es) Antibioticos de amplio espectro macrociclico.
MX2017009094A (es) Derivado de polimixina y usos del mismo.
WO2015112980A3 (en) Dermaseptin-type and piscidin-type antimicrobial peptides
WO2017218922A3 (en) Compositions and methods for the treatment of bacterial infections
ZA202002093B (en) Antibacterial compounds
MX2018006199A (es) Antibioticos de amplio espectro macrociclico.
MX2019015007A (es) Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
PH12019501904A1 (en) Macrocyclic broad spectrum antibiotics
WO2020014501A8 (en) Compositions and methods for the treatment of bacterial infections
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
EP3856213A4 (en) METHOD OF TREATMENT OF INFECTIONS USING BACTERIA